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INTRODUCTION
Acute mesenteric ischaemia presents infrequently 
in clinical practice accounting for 1-2 cases per 
1000 hospital admissions per year1. Of these, 
mesenteric vein thrombosis (MVT) is responsible 
for between 5% and 15% of intestinal ischaemic 
events2.  
Primary  mesenteric  vein  thromboses  are 
typically seen in patients with thrombophilias 
due to protein C, protein S and anti-thrombin 
III  deficiency. Approximately  2%  of  primary 
MVT  cases  are  caused  by  anti-thrombin  III 
deficiency3. Secondary MVT is commonly seen 
post-operatively,  with  oral  contraceptive  use, 
trauma or in paraneoplastic syndromes.    
Despite advances in diagnostic techniques and 
management  of  this  disease,  the  prognosis 
remains poor with mortality rates ranging from 
20% to 93%2,4.  We describe a case of primary 
MVT attributable to anti-thrombin III deficiency.
CASE REPORT
A 49-year-old man was admitted with a two-day history of 
worsening abdominal pain associated with nausea, vomiting, 
and  constipation.    His  past  medical  history  revealed  a 
background of two proximal deep venous thromboses (DVT) 
and an earlier diagnosis of anti-thrombin III deficiency.  He 
smoked over 30 cigarettes per day and consumed more than 
30 units of alcohol per week.  He had a family history of 
anti-thrombin III deficiency and many family members were 
already taking life long anticoagulation (figure 1).  The patient 
had been previously warfarinised following his DVTs, but 
latterly had been non-compliant.  On examination he was 
normotensive  but  tachycardic  with  abdominal  distension, 
guarding and absent bowel sounds. The degree of subjective 
pain was disproportionate to his objective tenderness.  Digital 
rectal examination was unremarkable. Initial investigations 
revealed a leucocytosis and elevated C-reactive protein.  A 
plain abdominal radiograph showed dilated bowel loops in the 
left flank.  Treatment with intravenous fluids, analgesia, anti-
emetics and broad-spectrum antibiotics was commenced.  An 
emergency computed tomograph of his abdomen was carried 
out in the portal venous phase; this showed thrombosis in the 
superior mesenteric vein extending to the portal confluence 
(figure 2) but the portal vein was patent.  Small bowel loops 
were dilated and oedematous, although not clearly necrotic, 
and there was free fluid in abdomen and pelvis.  On the 
basis of the clinical presentation and radiological findings, 
the  patient  was  taken  to  theatre  for  a  laparotomy.  Intra-
operatively a clearly demarcated venous infarct of the mid 
small bowel was found. A small bowel resection with primary 
anastomosis was performed.  The pathology report of the 
resected specimen confirmed small intestinal haemorrhage 
and  infarction  with  marked  transmural  inflammatory  cell 
infiltrate.
Post-operatively  he  was  transferred  to  the  intensive  care 
unit  where  he  subsequently  developed  a  severe  systemic 
inflammatory response. Over a period of several days, his 
clinical and biochemical parameters suggested ongoing sepsis 
but the aetiology of this was unclear. He therefore underwent 
a second look laparotomy, but no evidence of further bowel 
infarction  was  found.  Throughout  his  admission  to  the 
intensive care unit, the patient received full systemic support 
and was anti-coagulated with low molecular weight heparin. 
Fig 1. Anti-thrombin III deficiency in this patient’s family© The Ulster Medical Society, 2009.
54 The Ulster Medical Journal
www.ums.ac.uk
The efficacy of anti-coagulation was monitored with factor Xa 
assays. Despite this, he developed multiple organ dysfunction 
syndrome and required increasing ventilatory support, dialysis 
and addition of inotropes. He also developed liver failure 
(although  computed  tomography  showed  no  evidence  of 
further extension of thrombus into the portal vein) and he 
eventually died four weeks after initial presentation.
DISCUSSION
Diagnosis of intestinal ischaemia requires a high index of 
suspicion, regardless of the underlying cause. Many cases of 
MVT do not require surgical intervention and the decision 
to operate is based largely on clinical grounds where there 
is a strong possibility of bowel infarction. Attempts can be 
made to refine the diagnosis by blood testing; patients may 
present with a raised white cell count or metabolic acidosis, 
but neither is sensitive nor specific enough to aid definitive 
diagnosis of MVT.  Elevated D-dimer concentrations may 
also indicate bowel ischaemia, but similarly are not specific 
for  MVT5.  Imaging  modalities  such  as  plain  abdominal 
radiography can demonstrate bowel wall oedema and may 
exclude other causes of abdominal pain.  CT angiography is 
a more sensitive test for diagnosing thrombosis than CT or 
angiography alone. Magnetic resonance angiography is under 
review as a possible diagnostic tool for mesenteric ischaemia, 
but it lacks the resolution needed to diagnose non-occlusive 
mesenteric ischaemia or distal embolic disease.   
The  mainstay  of  medical  management  is  anticoagulation, 
and  immediate  heparinisation  has  been  shown  to  reduce 
recurrence and progression of the disease6.  However, use of 
heparin is more complicated in the context of anti-thrombin 
III  deficiency,  as  patients  with  reduced  concentrations  of 
anti-thrombin III are likely to be resistant to the effects of 
heparin and require larger doses. This may be attributable to 
the action of heparin, which binds to anti-thrombin, causing 
it to activate and inhibit thrombin. Anti-thrombin concentrate 
has been used effectively in patients with this deficiency and 
acute venous thrombosis, yet its use as an adjunctive therapy 
or alternative to heparin has not been studied in a controlled 
trial.      
Thrombolysis  with  streptokinase,  urokinase  and  tissue 
plasminogen activator (t-PA) has been used in treatment of 
MVT,  though  authors  have  recommended  that  its  use  be 
restricted  to  symptomatic  patients  with  early  diagnoses.   
Various routes for infusion of thrombolytics are described, 
including indirect intra-arterial infusion through the superior 
mesenteric artery and direct access to the portal vein with 
percutaneous  transhepatic  and  transjugular-intrahepatic 
approaches. It is felt that trans-arterial infusions are generally 
safer as they avoid potential bleeding complications that can 
result  from  liver  puncture  during  the  procedure,  however 
indirect lysis may be more unpredictable because of flow into 
collaterals7. These methods are preferred to use of systemic 
thrombolysis, owing to reduced haemorrhagic risk.  
A  further  treatment  option  is  mechanical  thrombectomy, 
which  provides  a  non-pharmacological  alternative  for 
treatment of MVT, particularly in patients who pose high 
risks for thrombolytic therapy. A combined approach using 
catheter-directed thrombolysis and mechanical thrombectomy 
has also been attempted with success though large-scale trials 
have not been undertaken8.  
Patients  presenting  with  peritonitis  or  identifiable  bowel 
infarction on CT require surgical management2,9,10. Options 
for surgical management of MVT include bowel resection 
with  primary  anastomosis,  temporary  stoma  formation, 
thrombectomy, or a combination of these techniques. The 
choice  of  surgical  management  depends  on  the  extent  of 
bowel infarction, bowel viability and whether it is possible 
following bowel resection to form a stoma2,10. It is also often 
difficult to absolutely ascertain bowel viability, although it 
can be assessed by direct observation of colour, presence of 
capillary refill and bowel contractility. This can be unreliable 
and  can  lead  to  more  bowel  resection  than  necessary9,10. 
There remains no consensus on whether or not a primary 
anastomosis should be attempted or a stoma created at the 
time of laparotomy10.  
Open thrombectomy is rarely undertaken as not all of the 
thrombus can be removed2,9,10, but its use in the treatment of 
acute superior mesenteric vein thrombosis when the thrombus 
is recently formed and restricted to the SMV may reduce the 
need for extensive bowel resection. Laparoscopy has been 
suggested as a diagnostic tool in identifying bowel ischaemia, 
but as it necessitates raising the intra-abdominal pressure and 
therefore decreasing mesenteric blood flow, it is probably 
best-avoided2.  
Diagnosis and management of primary MVT is complex. The 
condition may progress to full-blown portal vein thrombosis 
with more complications and a higher mortality. This case 
highlights the need to identify patients with MVT accurately 
and  efficiently  with  clear  implementation  of  medical  and 
surgical management, and how, even with apparently optimal 
treatment, the outcome may still be fatal.
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